JBCHEPHARM.BO · BSE
J.B.CHEMICALS & PHARMACEUTICAL
₹2,412.25
-3.73% (-₹93.35)
Prev. close
₹2,505.6
Volume
68,027
As of
16 Jul 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About J.B.CHEMICALS & PHARMACEUTICAL
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, capsules, liquids, gels, lozenges, creams, injectables, powder, cold rubs, eye drops, and troches; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, genecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.
Details
Key stats
Market cap
₹38,730.77 Cr
P/E ratio (TTM)
54.3
Dividend yield
0.77%
EPS (TTM)
₹44.39
Beta (1Y · daily vs NIFTY 50)
0.32
Beta (5Y · monthly vs NIFTY 50)
0.41
Shares float
8.14 Cr
EPS · quarter ended Mar 2026
₹6.32
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 1.1% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own reporting calendar.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,042.52 Cr | ₹2,424.24 Cr | ₹3,116.51 Cr | ₹3,447.67 Cr | ₹3,862.04 Cr | ₹4,076.20 Cr | |
| EBITDA | ₹672.79 Cr | ₹582.68 Cr | ₹705.05 Cr | ₹933.48 Cr | ₹1,069.12 Cr | ₹1,140.28 Cr |
| ₹448.52 Cr | ₹386.04 Cr | ₹409.84 Cr | ₹552.63 Cr | ₹659.58 Cr | ₹709.47 Cr | |
| Diluted EPS | — | ₹24.91 | ₹26.17 | ₹34.85 | ₹41.56 | — |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹3,553.87 Cr | ₹3,994.13 Cr | ₹4,273.78 Cr | ₹4,968.65 Cr | |
| — | — | ₹572.45 Cr | ₹377.66 Cr | ₹27.89 Cr | ₹3.59 Cr | |
| Stockholders' equity | — | — | ₹2,480.35 Cr | ₹2,923.33 Cr | ₹3,433.32 Cr | ₹4,159.22 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹625.61 Cr | ₹800.61 Cr | ₹902.45 Cr | ₹703.92 Cr | |
| Investing cash flow | — | — | ₹-961.79 Cr | ₹-403.83 Cr | ₹-295.90 Cr | ₹-585.88 Cr |
| — | — | ₹356.54 Cr | ₹-385.49 Cr | ₹-579.67 Cr | ₹-123.10 Cr | |
| Capital expenditure | — | — | ₹-764.95 Cr | ₹-261.37 Cr | ₹-120.31 Cr | ₹-83.19 Cr |
| End cash position | — | — | ₹76.93 Cr | ₹88.22 Cr | ₹115.09 Cr | ₹110.18 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
Documents
Annual reports
Show all 29
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.